Growth capital for biotechnology:
Yesterday, today, tomorrow!

A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 at the IZB - Innovation and Startup Center for Biotechnology to mark the 25th anniversary of biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies.

As an experienced specialist insurance broker for the life sciences, venture capital and IPOs sectors, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to hear the importance of customized risk management/insurance solutions from the discussions.

In particular, the more difficult financing environment post-2021 and the liability standards associated with decisions during the crisis had moved the industry. Our impression was also that people are looking even more to the USA for sources of financing than was the case years ago. The hope remains that we as Europeans and Germans will take the right steps via the EU Listing Act and the Future Financing Act. However, the discussions did not involve any groundbreaking changes for the biotech scene in Europe. All the more reason why our tips on US IPOs and references to our D&O flip concept were received with great interest. 

The same applies to the increase in IP disputes. The well-known disputes of the "BioTech" heavyweights and the effects of the new European Patent Court were discussed in small talk. We took away the desire/need to make what was discussed available for forwarding to the legal department with a view to risk management, which we were happy to take home with us as homework.

We are delighted to have been part of this event and will be at the start again for the next one. Thanks also to Karin Hofelich and Markus Rieger for the great organization and the successful setting of the event! It was great fun. We look forward to continuing to support life sciences companies and venture capital funds with our expertise in all phases for the next 25 years with leading risk and insurance concepts.